Akeso’s Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
HONG KONG, Sept. 30, 2024 /PRNewswire/ — September 30, 2024, Akeso (9926. HK) announced that its internally developed PD-1/CTLA-4 bispecific…
